Mouth cancer rates leap 68% in 20 years
Rates of mouth cancer have rocketed 68 percent in the UK in the least 20 years, according to new data released by Cancer Research UK.
Read More
Tag: mouth cancer
NICE rejects Merck’s Erbitux
The National Institute for Health and Care Excellence has decided that use of Merck’s head and neck cancer drug Erbitux is not cost-effective for the NHS in England and Wales.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
